Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna T...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

Murphydingle Mar. 20 at 9:15 PM

$NTLA rest up bulls, lick your wounds, the beat down continues next week

2 · Reply

Picklez_ Mar. 20 at 8:08 PM

$NTLA stocktwits in on the heist too, sure they can't update the volume.

1 · Reply

Picklez_ Mar. 20 at 8:02 PM

$NTLA what do you know 2mil in volume right after they drop the price, looks like covering to me.

1 · Reply

Murphydingle Mar. 20 at 7:52 PM

$NTLA the ripping and the tearing of the backside

0 · Reply

Murphydingle Mar. 20 at 7:38 PM

$NTLA lost all support levels, multiple channels, multiple Mas

1 · Reply

Murphydingle Mar. 20 at 7:37 PM

$NTLA getting absolutely destroyed, thats brutal, massive bag holders here

0 · Reply

TraderRoosevelt Mar. 20 at 7:19 PM

$NTLA why are bear comments on this site always ridiculous and spammy? This is a long play risky stock and it's still up 2% on the week and 40% on the year.

0 · Reply

Picklez_ Mar. 20 at 7:12 PM

$NTLA standard bullshit

0 · Reply

Murphydingle Mar. 20 at 7:10 PM

$NTLA 1pm on just straight selling waterfall down to the depths

1 · Reply

Murphydingle Mar. 20 at 6:57 PM

$NTLA there it is folks, a complete and utter loss of the 50 day ma, the 55 next and then the 200 as it trades back to the all time low throughout the year

0 · Reply

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 7:30 AM EST - 18 days ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 10:05 AM EST - 19 days ago

Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

Mar 2, 2026, 7:40 AM EST - 19 days ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 19 days ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 9:47 PM EST - 22 days ago

Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:30 AM EST - 23 days ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 24, 2026, 8:00 AM EST - 25 days ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:30 AM EST - 4 weeks ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 5, 2026, 1:55 PM EST - 6 weeks ago

Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026

Jan 27, 2026, 1:03 PM EST - 7 weeks ago

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

Jan 27, 2026, 8:13 AM EST - 7 weeks ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 2:16 PM EST - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 11:34 AM EST - 4 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID REPL SOC

Nov 10, 2025, 3:17 PM EST - 4 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 4 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 7, 2025, 5:46 AM EST - 4 months ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 5:11 PM EDT - 5 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 11:17 AM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 7:38 AM EDT - 5 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 24, 2025, 8:15 AM EDT - 5 months ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Sep 25, 2025, 1:57 PM EDT - 6 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 9:52 AM EDT - 6 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 19, 2025, 2:31 PM EDT - 6 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 7 months ago

Why big players are pouring millions in THIS biotech stock

Aug 15, 2025, 12:24 PM EDT - 7 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 7, 2025, 8:17 PM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 30, 2025, 11:07 AM EDT - 8 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

Jul 18, 2025, 8:00 AM EDT - 8 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jun 15, 2025, 10:45 AM EDT - 9 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

May 29, 2025, 11:25 AM EDT - 10 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 20, 2025, 5:47 AM EDT - 10 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

May 18, 2025, 7:25 AM EDT - 10 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 14, 2025, 1:57 PM EDT - 11 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 12, 2025, 9:07 AM EDT - 11 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 11 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:44 AM EDT - 11 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 11 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 11 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Murphydingle Mar. 20 at 9:15 PM

$NTLA rest up bulls, lick your wounds, the beat down continues next week

2 · Reply

Picklez_ Mar. 20 at 8:08 PM

$NTLA stocktwits in on the heist too, sure they can't update the volume.

1 · Reply

Picklez_ Mar. 20 at 8:02 PM

$NTLA what do you know 2mil in volume right after they drop the price, looks like covering to me.

1 · Reply

Murphydingle Mar. 20 at 7:52 PM

$NTLA the ripping and the tearing of the backside

0 · Reply

Murphydingle Mar. 20 at 7:38 PM

$NTLA lost all support levels, multiple channels, multiple Mas

1 · Reply

Murphydingle Mar. 20 at 7:37 PM

$NTLA getting absolutely destroyed, thats brutal, massive bag holders here

0 · Reply

TraderRoosevelt Mar. 20 at 7:19 PM

$NTLA why are bear comments on this site always ridiculous and spammy? This is a long play risky stock and it's still up 2% on the week and 40% on the year.

0 · Reply

Picklez_ Mar. 20 at 7:12 PM

$NTLA standard bullshit

0 · Reply

Murphydingle Mar. 20 at 7:10 PM

$NTLA 1pm on just straight selling waterfall down to the depths

1 · Reply

Murphydingle Mar. 20 at 6:57 PM

$NTLA there it is folks, a complete and utter loss of the 50 day ma, the 55 next and then the 200 as it trades back to the all time low throughout the year

0 · Reply

Murphydingle Mar. 20 at 6:44 PM

$NTLA about to lose the 50 day here, pain ahead, nasty selling

1 · Reply

Murphydingle Mar. 20 at 5:48 PM

$NTLA last shot for bulls to exit, gone, bears and shorts in full control

1 · Reply

Murphydingle Mar. 20 at 5:47 PM

$NTLA absolutely destroyed

0 · Reply

free2dream Mar. 20 at 4:53 PM

$XBI $XBI has a long ways to catch up the $SMH. Complaceny of shorts is surreal ,, and $XBI is extremely heavily shorted. $SRPT $NTLA $CLDX should see the biggest pop

0 · Reply

Murphydingle Mar. 20 at 2:10 PM

$NTLA fifth high shadow daily wick in a row

1 · Reply

Murphydingle Mar. 20 at 2:00 PM

$NTLA every pop sold and shorted into, massive resistance mid 13s they sell it every time

0 · Reply

goldenbluey Mar. 20 at 1:53 PM

$NTLA Dude. You sold at the wrong time. Get over it. Move on

1 · Reply

Murphydingle Mar. 20 at 9:58 AM

$NTLA they have absolutely no reason to cover

2 · Reply

Murphydingle Mar. 20 at 9:57 AM

$NTLA bulls already getting their asses clapped early, going to be a nasty red day

0 · Reply

Prettymoney4 Mar. 20 at 6:22 AM

$NTLA patience 🙃

0 · Reply

LongT Mar. 19 at 9:56 PM

$NTLA low volume day (2.7m). Down .03 for the day atm. SHORTS haven't covered jack yet. Just under 40% short interest. I'm stacking on dips whenever possible.

0 · Reply

Murphydingle Mar. 19 at 8:05 PM

$NTLA 4 high upper shadow wicks in a row, just brutal, heavy sellers here

0 · Reply

Market Cap	1.56B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	5,219,300
Avg Vol	5,052,546
Day's Range	N/A - N/A
Shares Out	118.13M
Stochastic %K	18%
Beta	2.10
Analysts	Sell
Price Target	$24.67